These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 12669769)

  • 1. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
    Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
    Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
    Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
    Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
    Acocella G; Nonis A; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):882-5. PubMed ID: 3202464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of examination in healthy volunteers of rifampicin and isoniazid bioavailability from Polish two-drug combination capsules of rifamazid used for tuberculosis treatment].
    Zofia Z; Niemirowska-Mikulska H; Augustynowicz-Kopeć E; Stambrowska A
    Pneumonol Alergol Pol; 1998; 66(3-4):198-206. PubMed ID: 9857665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation.
    Milán-Segovia RC; Domínguez-Ramírez AM; Jung-Cook H; Magaña-Aquino M; Romero-Méndez MC; Medellín-Garibay SE; Vigna-Pérez M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1454-60. PubMed ID: 20937187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability of rifampicin, isoniazid and ethambutol from a combination tablet vs. concomitant administration of a capsule containing rifampicin and a tablet containing isoniazid and ethambutol.
    Schall R; Müller FO; Duursema L; Groenewoud G; Hundt HK; Middle MV; Mogilnicka EM; Swart KJ
    Arzneimittelforschung; 1995 Nov; 45(11):1236-9. PubMed ID: 8929247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
    Panchagnula R; Singh I; Kaur KJ; Kaul CL
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):625-8. PubMed ID: 10669909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers.
    Padgaonkar KA; Revankar SN; Bhatt AD; Vaz JA; Desai ND; D'Sa S; Shah V; Gandewar K
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):627-31. PubMed ID: 10423226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.
    Acocella G; Nonis A; Perna G; Patane E; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):886-90. PubMed ID: 3202465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
    Acocella G; Luisetti M; Grassi GG; Peona V; Pozzi E; Grassi C
    Monaldi Arch Chest Dis; 1993; 48(3):205-9. PubMed ID: 8369784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V; Tekur U; Chopra K
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.
    Panchagnula R; Sancheti P; Rungta S; Agrawal S; Kaul CL
    Pharmacol Res; 2003 Oct; 48(4):383-7. PubMed ID: 12902209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence of fixed-dose combination Myrin®-P Forte and reference drugs in loose combination.
    Wang HF; Wang R; O'Gorman M; Crownover P; Naqvi A; Jafri I
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1596-601. PubMed ID: 24200275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects.
    Qurrat-ul-Ain ; Sharma S; Khuller GK; Garg SK
    J Antimicrob Chemother; 2003 Apr; 51(4):931-8. PubMed ID: 12654730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative bioavailability of isoniazid in a fixed-dose combination product in healthy Mexican subjects.
    Milán-Segovia RC; Vigna-Pérez M; Romero-Méndez MC; Medellín-Garibay SE; Vargas-Morales JM; Magaña-Aquino M; Romano-Moreno S
    Int J Tuberc Lung Dis; 2014 Jan; 18(1):49-54. PubMed ID: 24365552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Kaur KJ; Singh I; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2002 Feb; 233(1-2):169-77. PubMed ID: 11897421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.